Skip to main content
Daesung Microbiological Labs. Co. Ltd logo

Daesung Microbiological Labs. Co. Ltd — Investor Relations & Filings

Ticker · 036480 ISIN · KR7036480002 KO Manufacturing
Open in API
Filings indexed 126 across all filing types
Latest filing 2021-03-16 Audit Report / Informat…
Country KR South Korea
Listing KO 036480

About Daesung Microbiological Labs. Co. Ltd

https://eng.dsmbio.co.kr/

Daesung Microbiological Labs. Co., Ltd. is a company specializing in the development, manufacturing, and distribution of animal pharmaceuticals. Established in 1968, it is a leading vaccine manufacturer operating under KVGMP (Korean Veterinary Good Manufacturing Practice) standards. The company's product portfolio includes a comprehensive range of vaccines, antibiotics, parasiticides, and nutritional supplements. These products are designed for the health and well-being of livestock such as swine, bovine, and poultry, as well as for companion animals like canines. Daesung Microbiological Labs is committed to achieving disease-free livestock through continuous research and technological innovation in animal health.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a regulatory filing from Daesung Microbiological Labs titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion (unqualified/proper) and key financial data (assets, liabilities, revenue, profit) for the fiscal year. While it contains financial data, it is a short, standardized regulatory announcement notifying the market that the audit report has been submitted, rather than the full, multi-page audit report document itself. Therefore, it fits the definition of a Regulatory Filing (RNS) or a report publication announcement. FY 2020
2021-03-16 Korean
사업보고서 (2020.12)
Annual Report Classification · 1% confidence The document is a comprehensive 'Business Report' (사업보고서) for the fiscal year 2020, covering the period from January 1, 2020, to December 31, 2020. It includes detailed sections on company overview, business operations, financial statements, management discussion and analysis, and governance. This structure corresponds to the standard annual filing required by the Financial Supervisory Service (FSS) in South Korea, which is equivalent to the 10-K filing in the US market. FY 2020
2021-03-16 Korean
주주총회소집공고
AGM Information Classification · 1% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Daesung Microbiological Labs. It contains the agenda for the 55th Annual General Meeting, including reports on financial statements, director appointments, and remuneration limits. It also includes detailed management discussion and analysis (MDA) and financial statements (balance sheet, income statement, etc.) as part of the meeting materials provided to shareholders. This is a standard proxy solicitation and information statement package sent to shareholders to inform them of the meeting and request their votes.
2021-03-10 Korean
주주총회집중일개최사유신고
AGM Information Classification · 1% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the scheduling of a General Meeting of Shareholders on a 'concentrated date' (a date when many companies hold their meetings). It explains the reasoning for the chosen date and confirms the company's compliance status with the KOSDAQ Association's voluntary compliance program. Since it is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves, the proxy statement, or the voting results, it falls under the general regulatory filing category.
2021-03-10 Korean
주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Daesung Microbiological Labs. It outlines the date, location, agenda items (financial statement approval, director election, and remuneration), and details of the board candidates. This document serves as the official proxy solicitation and meeting notice provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon.
2021-02-23 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (Daesung Microbiological Labs) announcing a significant change (over 30%) in revenue or profit structure. This is a standard regulatory disclosure requirement in the Korean market (DART system) for material financial changes. Since it provides specific financial highlights and reasons for the variance rather than just announcing the availability of a report, it is classified as an Earnings Release (ER) equivalent in the context of regulatory disclosures. FY 2020
2021-02-08 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.